TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

TNF receptor 1 (TNFR1) is expressed in most cell ... selective targeting of TNFR1-mediated signaling while sparing TNFR2 activation may lessen adverse effects of anti-TNF therapies in the CNS.

J Neuroinflammation © 2008 McCoy and Tansey; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons ...

Nektar Therapeutics’s NKTR share price has surged by 6.77%, which has investors questioning if this is right time to sell.

Background Muscle wasting and weakness (sarcopenia) are commonly associated with COPD causing frailty and reduced quality of ...

TNF has emerged as an important factor in the pathogenesis of RA, and the inhibition of TNF signaling has proven ... in patients treated with the TNF receptor fusion protein etanercept, although ...

Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $590 - $605 million -- KPL-387 Phase 2/3 clinical trial ...

These negative outcomes may stem from disruptions in the one-carbon (1C) metabolic pathway, including impaired folic acid receptor ... and tumor necrosis factor-alpha (TNF-α).

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

With the introduction of a subcutaneous formulation, ENTYVIO has expanded patient convenience and global accessibility. Continued growth is supported by rising IBD prevalence and ongoing geographic ...

SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not ...